Victory Capital Management Inc. Sells 149,962 Shares of Haemonetics Co. (NYSE:HAE)

Victory Capital Management Inc. lessened its holdings in Haemonetics Co. (NYSE:HAE - Free Report) by 42.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 207,341 shares of the medical instruments supplier's stock after selling 149,962 shares during the quarter. Victory Capital Management Inc. owned 0.41% of Haemonetics worth $17,730,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. Knights of Columbus Asset Advisors LLC boosted its position in shares of Haemonetics by 1.3% in the third quarter. Knights of Columbus Asset Advisors LLC now owns 10,005 shares of the medical instruments supplier's stock valued at $896,000 after acquiring an additional 128 shares during the period. Parkside Financial Bank & Trust boosted its position in shares of Haemonetics by 17.4% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,054 shares of the medical instruments supplier's stock valued at $90,000 after acquiring an additional 156 shares during the period. Riverwater Partners LLC increased its position in shares of Haemonetics by 1.5% in the fourth quarter. Riverwater Partners LLC now owns 15,784 shares of the medical instruments supplier's stock worth $1,350,000 after purchasing an additional 231 shares during the period. Arizona State Retirement System raised its stake in Haemonetics by 1.7% in the third quarter. Arizona State Retirement System now owns 14,407 shares of the medical instruments supplier's stock valued at $1,291,000 after purchasing an additional 237 shares in the last quarter. Finally, Contravisory Investment Management Inc. lifted its position in Haemonetics by 7.4% during the fourth quarter. Contravisory Investment Management Inc. now owns 3,507 shares of the medical instruments supplier's stock worth $300,000 after purchasing an additional 242 shares during the period. Institutional investors own 99.67% of the company's stock.

Haemonetics Price Performance

Haemonetics stock traded up $3.30 during mid-day trading on Friday, reaching $95.90. The company had a trading volume of 445,064 shares, compared to its average volume of 463,513. The business has a fifty day simple moving average of $84.42 and a 200 day simple moving average of $82.93. The company has a market cap of $4.87 billion, a P/E ratio of 38.98, a P/E/G ratio of 2.23 and a beta of 0.34. The company has a current ratio of 2.92, a quick ratio of 1.76 and a debt-to-equity ratio of 0.91. Haemonetics Co. has a fifty-two week low of $70.74 and a fifty-two week high of $97.13.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $0.90 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.02. Haemonetics had a return on equity of 22.37% and a net margin of 9.97%. The company had revenue of $343.00 million for the quarter, compared to the consensus estimate of $329.53 million. During the same quarter last year, the business posted $0.77 EPS. Haemonetics's revenue for the quarter was up 12.7% on a year-over-year basis. On average, equities research analysts predict that Haemonetics Co. will post 3.95 earnings per share for the current year.

Insider Activity

In other Haemonetics news, EVP Anila Lingamneni sold 2,305 shares of the business's stock in a transaction that occurred on Monday, May 6th. The shares were sold at an average price of $95.00, for a total transaction of $218,975.00. Following the sale, the executive vice president now directly owns 12,295 shares of the company's stock, valued at approximately $1,168,025. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.79% of the company's stock.

Analyst Ratings Changes

Several research firms have commented on HAE. Needham & Company LLC reissued a "hold" rating on shares of Haemonetics in a report on Friday. StockNews.com cut Haemonetics from a "buy" rating to a "hold" rating in a research note on Friday, March 22nd. Barrington Research raised their target price on Haemonetics from $105.00 to $107.00 and gave the company an "outperform" rating in a report on Friday. TheStreet cut Haemonetics from a "b-" rating to a "c+" rating in a report on Thursday, February 29th. Finally, JMP Securities lifted their target price on Haemonetics from $115.00 to $125.00 and gave the company a "market outperform" rating in a research report on Friday. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $108.67.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.